bluebird bio Presents Updated Data from Phase 2/3 Starbeam Study of Investigational Lenti-D™ Gene Therapy for CALD and Initial Data from Observational Study ALD-103 of Allogeneic Hematopoi...
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
- Updated Efficacy and Safety Data Consistent with Previously Reported Phase 2/3 Starbeam Results – - General Agreement Reached on Regulatory Pathway for Lenti-D in the U.S. and EU – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the Phase 2/3 Starbeam study (ALD-102) of its investigational Lenti-D™ gene therapy in boys 17 years of age and under with cerebral adrenoleukodystrophy (CALD), and initial data from ALD-103, the ongoing observational study of outcomes from allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys 17 years of age and under with CALD. The data were presented today at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2018 Symposium in Athens, Greece. bluebird bio has also reached general agreement with the U.S. Food and Drug Administration (FDA) and the European Medicines Agen
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUEPR Newswire
- Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc. (BLUE) of a Class Action Lawsuit and an Upcoming DeadlineAccesswire
- BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit!Accesswire
- Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact Levi & KorsinskyAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- 3/26/24 - Form 8-K
- BLUE's page on the SEC website